IQVIA Data Show Uneven Biosimilar Uptake Across Drug Classes

By Gina ShawBiosimilars continue to expand their penetration in the U.S. market, but uptake remains highly variable across products, Scott Biggs, the director of supplier services at IQVIA, told attendees at the NASP 2025 Annual Meeting & Expo, in Denver.“Generics rapidly displace brands once exclusivity is lost,” Mr. Biggs said. “If biosimilars followed a similar trajectory, the savings for patients and the healthcare system would be enormous. But the reality is much more